InsidersTradesSigma
Follow the 力生制药 stock price and the full directors' dealings record of the company, a listed issuer based in China. Shares are quoted on CN CN, under the authority of SSE / SZSE (CSRC). The latest transaction was reported on 10 July 2026 (Sale). Among the most active insiders: 郭晓燕. The full history is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
力生制药 is a company focused on the research, development, and manufacturing of pharmaceutical products in China. It specializes in treatments for various diseases and medical conditions.